首页|血清IL-6R和IL-22表达与溃疡性结肠炎严重程度及临床结局的关系

血清IL-6R和IL-22表达与溃疡性结肠炎严重程度及临床结局的关系

扫码查看
目的 探究血清白细胞介素-6受体(IL-6R)和白细胞介素-22(IL-22)表达与溃疡性结肠炎严重程度及临床结局的关系。方法 选取监利市人民医院2017年12月至2022年6月治疗的212例溃疡性结肠炎病人为研究对象,根据其病情严重程度分为轻症组与重症组,根据治疗2个月的预后情况分为预后良好组与预后不良组,采用酶联免疫吸附测定检测IL-6R、IL-22水平并收集病人临床资料,logistic多因素回归分析影响溃疡性结肠炎病人预后的相关因素;绘制受试者操作特征曲线(ROC曲线)预测IL-6R和IL-22对溃疡性结肠炎严重程度以及预后的临床诊断及预测价值。结果 与轻症组[(11。10±1。21)ng/L、(50。24±6。35)ng/L]相比,重症组在入院时的血清IL-6R[(15。32±2。62)ng/L]、IL-22水平[(63。61±6。95)ng/L]显著增加(P<0。05),通过绘制ROC曲线发现IL-6R、IL-22以及两者联合诊断重症溃疡性结肠炎的曲线下面积(AUC)分别为0。85、0。85、0。92,并且二者联合诊断显著优于IL-6R、IL-22单独诊断(Z=3。58,3。42;P=0。003,0。006);通过分析病人一般临床资料发现,溃疡性结肠炎病人的预后与病人是否有肠外表现、C反应蛋白(CRP)、降钙素原(PCT)、红细胞沉降率(ESR)、粪便钙卫蛋白(FC)、粪便乳铁蛋白(FL)、IL-6R以及IL-22水平有关(P<0。05),与性别、年龄无关(P>0。05),logistic多因素回归分析发现,CRP、PCT、ESR、FC、FL、IL-6R以及IL-22均为影响溃疡性结肠炎病人预后的危险因素(P<0。05)。绘制ROC曲线发现IL-6R、IL-22以及两者联合预测溃疡性结肠炎病人预后的AUC分别为0。81、0。83、0。90,并且二者联合预测显著优于IL-6R、IL-22单独预测(Z=3。70,3。18;P<0。001,P=0。002)。结论 溃疡性结肠炎病人血清IL-6R、IL-22水平随病人病情严重程度增加,均为影响溃疡性结肠炎病人预后的危险因素,并且对病人的病情严重程度及临床结局预测具有辅助诊断价值。
Relationship between the expression of serum IL-6R and IL-22 and the severity and clinical outcome of ulcerative colitis
Objective To explore the relationship between the expression of serum interleukin-6 receptor(IL-6R)and interleukin-22(IL-22)and the severity and clinical outcome of ulcerative colitis.Methods Two hundred and twelve patients with ulcerative colitis treated in Jianli People's Hospital from December 2017 to June 2022 were as research objects,according to the severity of their condi-tion,they were grouped into mild and severe group,according to the prognosis after 2 months of treatment,they were grouped into a good prognosis group and a poor prognosis group,enzyme linked immunosorbent assay(ELISA)was applied to detect IL-6R and IL-22 levels,and clinical data were collected from patients,Logistic regression was applied to analyze the related factors affected the progno-sis of patients with ulcerative colitis;receiver operating characteristic was drawn to predict the clinical diagnostic and predictive value of IL-6R and IL-22 for severity and prognosis of ulcerative colitis.Results Compared with the mild group[(11.10±1.21)ng/L,(50.24±6.35)ng/L],the serum levels of IL-6R[(15.32±2.62)ng/L]and IL-22[(63.61±6.95)ng/L]in the severe group were obviously increased at admission(P<0.05),by drawing the receiver operating characteristic,it was found that the AUC of IL-6R,IL-22 and their combined diagnosis of severe ulcerative colitis was 0.85,0.85 and 0.92,respectively,and their combined diagnosis was obviously better than that of IL-6R and IL-22 alone(Z=3.58,3.42;P=0.003,0.006);by analyzing the general clinical data of the patients,it was found that the prognosis of patients with ulcerative colitis was related to whether they had extraintestinal manifestations,C-reactive protein(CRP),pro-cal-citonin(PCT),erythrocytesedimentrate(ESR),faecal calreticulin(FC),faecal lactoferrin(FL),IL-6R and IL-22 levels(P<0.05),but not to gender and age(P>0.05),multiple Logistic regression analysis showed that CRP,PCT,ESR,FC,FL,IL-6R and IL-22 were all risk factors affecting the prognosis of ulcerative colitis patients(P<0.05).Receiver operating characteristic found that the AUC of pa-tients with ulcerative colitis predicted by IL-6R,IL-22 and their combination was 0.81,0.83 and 0.90,respectively,and their combined predicted was obviously better than that predicted by IL-6R and IL-22 alone(Z=3.70,3.18;P<0.001,P=0.002).Conclusion The serum levels of IL-6R and IL-22 in patients with ulcerative colitis increase with the severity of the patient's disease,both are both risk factors affecting the prognosis of patients with ulcerative colitis,and they have an auxiliary diagnostic value in the prediction of the severity of the patient's disease and clinical outcome.

Colitis,ulcerativeInterleukin-6 receptorInterleukin-22Severity of the conditionClinical outcomes

费良、刘红霞、赵敬贤、颜悦蓉、聂琳

展开 >

监利市人民医院,消化内科,湖北 监利 433000

监利市人民医院,急诊科,湖北 监利 433000

湖北文理学院附属襄阳市中心医院消化内科,湖北 襄阳 441021

结肠炎,溃疡性 白细胞介素-6受体 白细胞介素-22 病情严重程度 临床结局

2025

安徽医药
安徽省药学会

安徽医药

影响因子:1.941
ISSN:1009-6469
年,卷(期):2025.29(1)